In early January, MAPS announced that MAPP2 met pre-specified primary and key secondary endpoints and that it planned to file a new drug application submission in the third quarter of 2023.
At the end of the Phase 3 MAPP2 study, two-thirds of MDMA recipients no longer met PTSD diagnostic criteria compared to one-third of placebo recipients.
Doblin also expects other psychedelic compounds, such as psilocybin and ibogaine, to win FDA approval.
Originally appearing here (Archived)
